Evidence map›Paper›PMID 37895929›Full record

ArticlePharmaceuticals (Basel, Switzerland)2023

Adenylosuccinic Acid Is a Non-Toxic Small Molecule In Vitro and In Vivo.

Cara A Timpani, Lorna Rasmussen, Emma Rybalka

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 2 countries.

Cara A TimpaniInstitute for Health and Sport (IHeS), Victoria University, Melbourne, VIC 8001, Australia.ORCID 0000-0003-4567-4319
Lorna RasmussenCerberus Sciences, Scoresby, VIC 3179, Australia.
Emma RybalkaInstitute for Health and Sport (IHeS), Victoria University, Melbourne, VIC 8001, Australia.ORCID 0000-0002-4854-0036
The University of Melbourne · AU

Funding

Australian Institute for Musculoskeletal Science N/A
6 · The paper itself

Abstract

Adenylosuccinic acid (ASA) is a small molecule dicarboxylate that could be a strong clinical development candidate for inherited myopathies involving dysregulated purine nucleotide metabolism. Currently, there are no published pharmacokinetic/dynamic or toxicology data available, although 10-year clinical trial data on Duchenne muscular dystrophy patients suggests it is a chronically safe drug. In this study, we tested the toxicity of ASA to cultured myoblasts in vitro and its acute systemic toxicity in mice. ASA is a non-toxic small molecule with an LD

Indexed as

adenylosuccinic aciddrug developmentDuchenne muscular dystrophymetabolic diseasemyopathyskeletal muscletoxicology

Identifiers

PMID37895929
PMCPMC10609790
OpenAlexW4387618052

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.